Clinical Trial Update: A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for JNJ-54781532 in moderately to severely active ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• JNJ-54781532

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Colitis, Ulcerative | Phase 2 | Status: COMPLETED